Abstract
Acquired immune deficiency syndrome (AIDS) is an infectious disease characterized by severe impairment of the patient's cell-mediated immune system1,2. Several lines of evidence have indicated that the aetiological agent of AIDS is a group of T-lymphotropic retroviruses, variously known as lymphadenopathy-associated virus (LAV)3, human T-lymphotropic virus type III (HTLV-III)4,5 and AIDS-associated retrovirus (ARV)6. Serologi-cal surveys have indicated that as many as one million people in the United States may have been infected by LAV/HTLV-III7, and the spread of AIDS has become a global concern. The need for a better understanding of the viral immunology and for a vaccine against AIDS is self-evident. To this end, we have constructed recombinant vaccinia viruses containing the envelope (env) gene of LAV, and demonstrate here that cells infected with these viruses express immunoreactive proteins similar to those present on LAV virions. Experimental animals infected with these recombinant viruses elicited antibodies that specifically recognized LAV envelope proteins.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 51 print issues and online access
$199.00 per year
only $3.90 per issue
Buy this article
- Purchase on SpringerLink
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Gottlieb, M. et al. New Engl. J. Med. 305, 1426–1431 (1981).
Masur, H. et al. New Engl. J. Med. 305, 1431–1438 (1981).
Barré-Sinoussi, F. et al. Science 220, 868–870 (1983).
Gallo, R. C. et al. Science 224, 500–502 (1984).
Popovic, M., Sarngadharan, M. G., Read, E. & Gallo, R. C. Science 224, 497–499 (1984).
Levy, J. A. et al. Science 225, 840 (1984).
Curran, J. W. et al. Science 229, 1352–1357 (1985).
Alizon, M. et al. Nature 312, 757–760 (1985).
Wain-Hobson, S., Sonigo, P., Danos, O., Cole, S. & Alizon, M. Cell 40, 9–17 (1985).
Mackett, M., Smith, G. L. & Moss, B. J. Virol. 49, 857–864 (1984).
Montagnier, L. et al. Virology 144, 283–289 (1985).
Robey, W. G. et al. Science 228, 593–595 (1985).
Robert-Guroff, M., Brown, M. & Gallo, R. C. Nature 316, 72–74 (1985).
Panicali, D. & Paoletti, E. Proc. natn. Acad. Sci. U.S.A. 79, 4927–4931 (1982).
Mackett, M., Smith, G. & Moss, B. Proc. natn. Acad. Sci. U.S.A. 79, 7415–7419 (1982).
Smith, G. L., Mackett, M. & Moss, B. Nature 302, 490–495 (1983).
Panicali, D., Davis, S. W., Weinberg, R. L. & Paoletti, E. Proc. natn. Acad. Sci. U.S.A. 80, 5364–5368 (1983).
Smith, G. L., Murphy, B. R. & Moss, B. Proc. natn. Acad. Sci. U.S.A. 80, 7155–7159 (1983).
Paoletti, E. et al. Proc. natn. Acad. Sci. U.S.A. 81, 193–197 (1984).
Bennick, J. R. et al. Nature 311, 578–579 (1984).
Maniatis, T., Fritsch, E. F. & Sambrook, J., (eds) Molecular Cloning: A Laboratory Manual (Cold Spring Harbor Laboratory, New York, 1982).
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Hu, SL., Kosowski, S. & Dalrymple, J. Expression of AIDS virus envelope gene in recombinant vaccinia viruses. Nature 320, 537–540 (1986). https://doi.org/10.1038/320537a0
Received:
Accepted:
Issue date:
DOI: https://doi.org/10.1038/320537a0
This article is cited by
-
The optimization of helper T lymphocyte (HTL) function in vaccine development
Immunologic Research (1998)
-
Identification of three N-linked glycans in the V4–V5 region of HIV-1 gp 120, dispensable for CD4-binding and fusion activity of gp 120
Archives of Virology (1994)
-
Implications of HIV specific cytotoxic T lymphocytes in AIDS
Biotherapy (1992)
-
An O-linked carbohydrate neutralization epitope of HIV-1 gp 120 is expressed by HIV-1env gene recombinant vaccinia virus
Archives of Virology (1992)
-
Serum antibodies to HIV-1 in recombinant vaccinia virus recipients boosted with purified recombinant gp160
Journal of Clinical Immunology (1992)
